TRINITY BIOTECH PLC DUBLIN, Ireland, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2021.
Quarter 2 Results
Total revenues for Q2, 2021 were $25.8m, which compares to $16.0m in Q2, 2020, an increase of $9.8m and which were broken down as follows:
| 2020 Quarter 2 | 2021 Quarter 2 | Increase | ||
| US$’000 | US$’000 | % | ||
| Point-of-Care | 1,267 | 1,958 | 54.5% | |
| Clinical Laboratory | 14,757 | 23,885 | 61.9% | |
| Total | 16,024 | 25,843 | 61.3% | |
Point-of-Care revenues for Q2, 2021 increased from $1.3m to $2.0m when compared to Q2, 2020, an increase of almost 55%. This increase was attributable to higher HIV revenues from Africa related sales. In Q2 2020, revenues were significantly impacted by logistical constraints caused by COVID-19. While these constraints have eased somewhat, COVID-19 continues to disrupt HIV testing in Africa and the associated purchase of Point-of-Care tests.
Clinical Laboratory revenues increased from $14.8m to $23.9m, which represents an increase of 61.9% compared to Q2, 2020. The increase is mainly due to strong revenues from within our COVID-19 related portfolio of products, with our PCR Viral Transport Media product being the most significant contributor to revenue within that portfolio. The Company noted a significant reduction in demand for new orders of VTM during early 2021 as COVID-19 testing volumes dropped and customers utilised stockpiled product. As such Q2 2021 VTM revenue primarily derived from closing out existing orders. While the situation relating to COVID-19 products remains very fluid, with the evolving impact of the Delta variant the Company has seen increased customer interest in VTM products over recent weeks and is taking steps to address any increase in demand that materialises.
In addition to increases in revenues from products within our COVID-19 portfolio of products, there was a significant increase in our Haemoglobins and Autoimmunity business in Q2 2021 compared to Q2 2020 as while COVID-19 public health restrictions remained in place, in many markets these restrictions were not as severe as in Q2 2020, thus allowing a partial return towards more normalised level of Haemoglobins and Autoimmunity testing.
Gross profit for Q2, 2021 amounted to $11.0m, representing a gross margin of 42.7%. This is broadly similar to the 42.9% achieved in Q2, 2020.
Other operating income increased from $2,000 in Q2 2020 to $2.9m in Q2 2021. The $2.9m income relates to loan funding received in 2020 under the U.S. government’s Paycheck Protection Program (“PPP”). Four PPP loans received by the Company in 2020, totalling $2.9m, were forgiven during Q2 2021 and have therefore been recognised as income this quarter. These four loans were treated as short term liabilities at March 31, 2021.
Research and Development expenses decreased slightly to $1.1m, whilst Selling, General and Administrative (SG&A) expenses increased by $1.3m to $6.3m when compared to Q2, 2020. SG&A expenses were unusually low in Q2 2020, due to the furloughing of employees as a result of the pandemic, government payroll supports related to COVID-19 which are not being claimed in 2021 and other cost savings. Q2 2021 SG&A costs include higher professional fees and sales team related costs compared to Q2 2020.
Operating profit for the quarter was $6.3m, which represents an increase of $5.8m compared to Q2, 2020 and was attributable to increased revenues and other operating income offset slightly by a lower gross margin and higher indirect costs.
Financial Expenses amounted to $1.2m, which was in line with Q2, 2020. Of this, $1.0m related to interest payable on the Company’s Exchangeable Notes, with the remaining $0.2m representing notional financing charges arising on leased assets (IFRS 16). Non-cash financial income of $0.9m was recognised in this quarter’s income statement, again in relation to the Exchangeable Notes. This was due to a notional gain of $1.0m arising due to a decrease in the fair value of the derivatives embedded in these notes as required by IFRS 9, partially offset by accretion interest on the Exchangeable Notes of $0.1m.
The profit before tax, (before the impact of impairment, non-cash financial items and once-off charges) for the quarter was $5.1m, in comparison to a loss of $0.7m for the equivalent period last year.
The basic earnings per ADR (our equivalent to EPS) (excluding impairment, once-off charges and non-cash financial items) for the quarter was 21.2 U.S. cents versus a loss per ADR of 3.6 U.S. cents in Q2, 2020. Unconstrained diluted EPS (excluding impairment, once-off charges and non-cash financial items) for the quarter amounted to 20.3 U.S. cents, which compares to 1.0 U.S. cent in the equivalent quarter in 2020.
Earnings before interest, tax, depreciation, amortisation and share option expense (EBITDASO) for the quarter was $7.4m, and was made up as follows:
| $m | |
| Operating Profit | 6.3 |
| Depreciation | 0.6 |
| Amortisation | 0.2 |
| Share Option Expense | 0.3 |
| EBITDASO | 7.4 |
The above measures exclude the impact of impairment charges amounting to $6.1m, more details of which are provided below.
Cash Flow
The Group’s cash balance reduced by $3.7m in Q2 2021. This cash reduction was driven by a $2m interest payment on the Exchangeable Notes, working capital movements and capital expenditure.
For instance, trade & other payables reduced by c$9.6m compared to Q1 2021. This reduction was mainly driven by the aforementioned forgiveness of the PPP loans, and a reduction in trade creditors & accruals as the Company paid VTM related suppliers for previously supplied raw materials while reducing the level of purchases of raw materials to reflect the reduced new orders for VTM products as the quarter continued.
Impairment
In accordance with the provisions of accounting standards under IFRS, a company is required to carry out periodic impairment reviews in order to determine the appropriate carrying value of its net assets. This period’s review has resulted in a non-cash impairment charge of $6.1m net of tax being recognised. A number of factors impacted this calculation including the Company’s share price at 30 June 2021 which was lower than the share price at the time of the prior impairment review (31 December 2020), cash flow projections and net asset values across each of the Company’s individual main business lines.
Business Developments
HIV Testing (TrinScreen™ HIV)
Trinity Biotech has been the main confirmatory test provider for the detection of the HIV virus on the African continent over many years. Trinity Biotech has developed a new product, TrinScreen™ HIV, specifically for the screening market, a market that is significantly larger than the confirmatory market. TrinScreen™ HIV has already undergone an independent evaluation sponsored by the World Health Organisation (WHO), yielding excellent results. The final part of the approval process includes WHO review of the multi-site clinical evaluation which concluded in Africa in 2020. This final part of the submission dossier was submitted to the WHO in March 2021.
In June 2021, the Company received an update from the WHO on the approval process. The WHO confirmed that their screening of the submission dossier was complete and the dossier was to move forward to the final assessment phase.
In September 2021 the Company received a further update from the WHO on the approval process. The WHO confirmed that the final assessment phase is now well advanced. This is yet another important milestone in the approval process for TrinScreen™ HIV. This product, once approved, will allow the Company to build on its strong brand presence in HIV testing in Africa. The Company believes the TrinScreen™ HIV product has a number of key advantages compared to the current main incumbent product and expects a positive response from the WHO and the opportunity to expand its market share in the African HIV market.
The Company is preparing for the automated manufacture of TrinScreen™ HIV at its facility in Ireland in anticipation of WHO approval.
COVID-19 Rapid Antigen Test
In Q1 2021, the Company began a R&D process transformation programme. The objectives of this programme are to deliver new high quality products to the market faster and at a lower cost of production so as to allow the Company capture a greater market share and deliver higher profitability. To deliver on these objectives, the transformation programme has focused on optimising the core R&D processes and integrating these with manufacturing readiness and the regulatory approval process.
Our COVID-19 rapid antigen test is the first product development project to be brought through this revised R&D process. As a result of an expectation of higher demand due to the impact of the Delta variant, the Company has also decided to increase the priority of this test and is committing additional internal resources to the development of this test in the short term. The streamlined R&D process, coupled with targeted additional internal resource allocation has significantly reduced our expected time to market. As such, we now expect that we will have achieved CE mark during Q2 2022 which will allow us to launch the product in Europe. While we do expect to launch the product in the US, the regulatory path for such products remains fluid and thus the Company will continue to assess what may be the most appropriate regulatory approval pathway to allow a US launch of the product.
The COVID-19 rapid antigen test can be run without any specialised equipment, provides a result in 12 minutes and utilises an easy-to-use anterior nasal swab sample. The test design has demonstrated excellent analytical results, and the focus for the remainder of the development process will be on transfer to automated manufacture and clinical validation. The COVID-19 rapid antigen test is built on the same core lateral flow technology as our TrinScreen HIV test and thus the Company has significant automated manufacturing capacity to produce the test.
The core lateral flow technology is customisable for many test types, and we expect to continue to expand our test offering with this test platform and leverage the cost benefits of common manufacturing processes. We intend to further expand the test menu in Infectious Disease in 2022 with a focus on high volume markets to capitalise on the synergies of our Sales, Marketing and Distribution capabilities and existing relationships with NGO’s.
Comments
Commenting on the results John Gillard, Chief Financial Officer stated, “The Company delivered another strong quarter in Q2 2021 with gross profit of $11m compared to $6.9m in Q2 2020. This translated into an operating profit (before impairments) for Q2 2021 of $6.3m compared to $0.5m in Q2 2020.”
Ronan O’Caoimh, Chief Executive Officer stated, “We are pleased to have another strong quarter with a 61% increase in revenue compared to Q2 2020, primarily driven by strong revenues from within our COVID-19 related portfolio of products and a partial rebound in our core revenues.
In addition, we have made significant progress in streamlining our R&D processes with the aim of bringing new high quality products to market faster and at a lower cost of production so as to allow the Company capture a greater market share and deliver higher profitability, particularly in our lateral flow business. We are excited that these changes should allow us expand our range of lateral flow tests more quickly and efficiently. For instance, this revised process is allowing us bring forward the expected CE mark and European launch of our COVID-19 rapid antigen test to Q2 2022, which is several quarters earlier than our initial development plan. The test can be run without any specialised equipment, provides a result in 12 minutes and utilises an easy-to-use anterior nasal swab sample.
Given the evidence of breakthrough infections for those vaccinated and the continuing threat of new variants, we now expect rapid antigen testing to have a continuing place in the overall public health response to COVID-19, even as vaccinations continue and that this may be a significant market for Trinity Biotech into the future. As such we have prioritised the allocation of internal resources with the intent of bringing this test to market earlier than initially planned.”
The above mentioned numbers are unaudited.
Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of Trinity Biotech to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the results of research and development efforts, risks associated with the outbreak and global spread of the coronavirus (COVID-19), the effect of regulation by the U.S. Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties. For additional information regarding these and other risks and uncertainties associated with Trinity Biotech’s business, reference is made to our reports filed from time to time with the U.S. Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements for any reason.
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.
| Trinity Biotech plc Consolidated Income Statements | |||||||||
| (US$000’s except share data) | Three Months Ended June 30, 2021 (unaudited) | Three Months Ended June 30, 2020 (unaudited) | Six Months Ended June 30, 2021 (unaudited) | Six Months Ended June 30, 2020 (unaudited) | |||||
| Revenues | 25,843 | 16,024 | 51,437 | 37,201 | |||||
| Cost of sales | (14,816 | ) | (9,153 | ) | (29,497 | ) | (21,053 | ) | |
| Gross profit | 11,027 | 6,871 | 21,940 | 16,148 | |||||
| Gross margin % | 42.7 | % | 42.9 | % | 42.7 | % | 43.4 | % | |
| Other operating income | 2,906 | 2 | 2,907 | 16 | |||||
| Research & development expenses | (1,056 | ) | (1,153 | ) | (2,493 | ) | (2,531 | ) | |
| Selling, general and administrative expenses | (6,280 | ) | (5,006 | ) | (12,300 | ) | (11,091 | ) | |
| Indirect share based payments | (311 | ) | (213 | ) | (690 | ) | (348 | ) | |
| Operating profit | 6,286 | 501 | 9,364 | 2,194 | |||||
| Financial income | 1 | 2 | 2 | 34 | |||||
| Financial expenses | (1,202 | ) | (1,221 | ) | (2,412 | ) | (2,453 | ) | |
| Net financing expense | (1,201 | ) | (1,219 | ) | (2,410 | ) | (2,419 | ) | |
| Profit/(Loss) before tax , impairment, once-off & non-cash items | 5,085 | (718 | ) | 6,954 | (225 | ) | |||
| Income tax expense | (655 | ) | (32 | ) | (760 | ) | (162 | ) | |
| Profit/(Loss) after tax before impairment, once-off & non-cash items | 4,430 | (750 | ) | 6,194 | (387 | ) | |||
| Non-cash financial income/(expense)* | 855 | (717 | ) | 693 | (877 | ) | |||
| Impairment & once-off items | (6,068 | ) | - | (6,068 | ) | (2,425 | ) | ||
| Profit/(Loss) after tax | (783 | ) | (1,467 | ) | 819 | (3,689 | ) | ||
| Earnings/(Loss) per ADR (US cents) | (3.7 | ) | (7.0 | ) | 3.9 | (17.6 | ) | ||
| Earnings/(Loss) per ADR (US cents)*** | 21.2 | (3.6 | ) | 29.6 | (1.9 | ) | |||
| Diluted earnings per ADR (US cents)** | 20.3 | 1.0 | 30.3 | 6.3 | |||||
| Weighted average no. of ADRs used in computing basic earnings per ADR | 20,901,703 | 20,901,703 | 20,901,703 | 20,901,703 | |||||
| Weighted average no. of ADRs used in computing diluted earnings per ADR | 26,728,320 | 25,931,574 | 27,008,193 | 25,745,569 | |||||
*Non-cash financial income/(expense) refers to accretion interest and fair value adjustments.
** Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. In a reporting period where it is anti-dilutive, diluted earnings per ADR should be constrained to equal basic earnings per ADR. Diluted EPS is calculated excluding impairment, once-off charges & non-cash financial items.
*** Excluding impairment, once-off charges & non-cash financial items.
The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting). Impairment, once-off charges & non-cash financial items are non-GAAP accounting presentations.
| Trinity Biotech plc Consolidated Balance Sheets | ||||||
| June 30, 2021 US$ ‘001 (unaudited) | Mar 31, 2021 US$ ‘000 (unaudited) | Dec 31, 2020 US$ ‘000 (unaudited) | ||||
| ASSETS | ||||||
| Non-current assets | ||||||
| Property, plant and equipment | 6,501 | 8,648 | 8,547 | |||
| Goodwill and intangible assets | 32,864 | 35,200 | 33,860 | |||
| Deferred tax assets | 3,617 | 4,205 | 4,185 | |||
| Other assets | 279 | 315 | 355 | |||
| Total non-current assets | 43,261 | 48,368 | 46,947 | |||
| Current assets | ||||||
| Inventories | 34,705 | 37,582 | 30,219 | |||
| Trade and other receivables | 15,358 | 14,864 | 22,668 | |||
| Income tax receivable | 2,782 | 2,888 | 3,086 | |||
| Cash, cash equivalents and deposits | 28,618 | 32,277 | 27,327 | |||
| Total current assets | 81,463 | 87,611 | 83,300 | |||
| TOTAL ASSETS | 124,724 | 135,979 | 130,247 | |||
| EQUITY AND LIABILITIES | ||||||
| Equity attributable to the equity holders of the parent | ||||||
| Share capital | 1,213 | 1,213 | 1,213 | |||
| Share premium | 16,187 | 16,187 | 16,187 | |||
| Treasury shares | (24,922 | ) | (24,922 | ) | (24,922 | ) |
| Accumulated surplus | 12,093 | 12,561 | 10,573 | |||
| Translation reserve | (5,090 | ) | (5,189 | ) | (5,293 | ) |
| Other reserves | 23 | 23 | 23 | |||
| Total deficit | (496 | ) | (127 | ) | (2,219 | ) |
| Current liabilities | ||||||
| Income tax payable | 751 | 389 | 154 | |||
| Trade and other payables | 21,304 | 30,881 | 26,488 | |||
| Exchangeable senior note payable¹ | 83,190 | - | - | |||
| Provisions | 376 | 376 | 416 | |||
| Total current liabilities | 105,621 | 31,646 | 27,058 | |||
| Non-current liabilities | ||||||
| Exchangeable senior note payable¹ | - | 84,045 | 83,884 | |||
| Other payables | 15,283 | 15,625 | 16,619 | |||
| Deferred tax liabilities | 4,316 | 4,790 | 4,905 | |||
| Total non-current liabilities | 19,599 | 104,460 | 105,408 | |||
| TOTAL LIABILITIES | 125,220 | 136,106 | 132,466 | |||
| TOTAL EQUITY AND LIABILITIES | 124,724 | 135,979 | 130,247 | |||
¹ Exchangeable senior notes having a nominal value of US$99.9 million mature on April 1, 2045, subject to earlier repurchase, redemption or exchange. The exchangeable notes (and the related embedded derivatives) have been presented within current liabilities at June 30, 2021 as the Company does not have an unconditional right to defer settlement of the exchangeable notes for at least 12 months after the reporting period due to the existence of a put option which allows the holders to put the exchangeable notes to the issuer at par on April 1, 2022. This accounting treatment of the exchangeable notes is required by IAS 1. Additional information relating to the accounting treatment for the exchangeable notes may be found in the Company’s Annual Report on Form 20-F filing filed with the U.S. Securities and Exchange Commission.
The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).
| Trinity Biotech plc Consolidated Statement of Cash Flows | ||||||||
| (US$000’s) | Three Months Ended June 30, 2021 (unaudited) | Three Months Ended June 30, 2020 (unaudited) | Six Months Ended June 30, 2021 (unaudited) | Six Months Ended June 30, 2020 (unaudited) | ||||
| Cash and cash equivalents at beginning of period | 32,277 | 13,244 | 27,327 | 16,400 | ||||
| Operating cash flows before changes in working capital | 4,460 | 1,311 | 8,524 | 3,779 | ||||
| Changes in working capital | (3,155 | ) | 1,471 | (1,326 | ) | 74 | ||
| Cash generated from operations | 1,305 | 2,782 | 7,198 | 3,853 | ||||
| Net Interest and Income taxes (paid)/received | (92 | ) | (34 | ) | 98 | 397 | ||
| Capital Expenditure & Financing (net) | (2,154 | ) | (2,163 | ) | (4,350 | ) | (4,919 | ) |
| Payments for Leases (IFRS 16) | (720 | ) | (781 | ) | (1,421 | ) | (1,571 | ) |
| Free cash flow | (1,661 | ) | (196 | ) | 1,525 | (2,240 | ) | |
| Payment of HIV/2 License Fee | - | - | - | (1,112 | ) | |||
| 30 year Exchangeable Note interest payment | (1,998 | ) | (1,998 | ) | (1,998 | ) | (1,998 | ) |
| Proceeds received under Paycheck Protection Program | - | 4,520 | 1,764 | 4,520 | ||||
| Cash and cash equivalents at end of period | 28,618 | 15,570 | 28,618 | 15,570 | ||||
The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).
| Contact: | Trinity Biotech plc | Lytham Partners, LLC |
| John Gillard | Joe Diaz | |
| (353)-1-2769800 | (1)-602-889-9700 | |
| E-mail: investorrelations@trinitybiotech.com |
